7NS0 Stock Chart & Stats
€5.01
€0.00(0.00%)
At close: 4:00 PM EDT
€5.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€5.01 - €5.36
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€223.67M
Enterprise Value€316.62M
Total Cash (Recent Filing)€125.17M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
BetaN/A
Next Earnings
Nov 16, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding174,270,550
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)1.01
Price to Sales (P/S)0.00
P/FCF Ratio-12.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€9.77Price Target Upside95.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.2
Revenue Forecast (FY)€374.66K
Bulls Say, Bears Say
Bulls Say
Low Leverage And Sizable Equity BaseMinimal debt and a sizable equity base provide financial flexibility for a development-stage biotech. This structure reduces leverage-related pressure and supports continued clinical execution, although the company remains dependent on its capital base while it has no meaningful product revenue.
FDA Clearance Advances Crohn’s Disease ProgramFDA clearance is a durable development milestone because it enables a Phase 2 study in moderate to severe Crohn’s disease. Advancing into a later clinical stage broadens the pipeline’s potential commercial opportunity and creates a defined path toward future efficacy data.
Canadian Clearance Expands Global Phase 2 ExecutionHealth Canada’s CTA clearance expands the geographic reach of the ulcerative colitis study and supports planned enrollment. This regulatory progress strengthens the company’s ability to execute a global trial and generate clinical evidence across another important GI indication.
Bears Say
Pre-revenue Business ModelThe absence of meaningful revenue leaves Palisade reliant on clinical development progress rather than recurring commercial cash inflows. Until a candidate is successfully developed and commercialized, operating performance will remain highly exposed to trial outcomes and funding requirements.
Widening Net LossesThe sharp increase in net losses indicates that spending is rising faster than the business is generating economic returns. Persistent loss expansion can consume the equity base, increase future financing needs, and limit financial flexibility if clinical development takes longer than planned.
Increasing Cash BurnFree cash flow remains negative and deteriorated materially from the prior period, showing that ongoing operations consume substantial cash. If this burn rate persists through Phase 2 development, Palisade may need additional funding before its programs can produce commercial cash flow.
Palisade Bio News
7NS0 FAQ
What was Palisade Bio’s price range in the past 12 months?
Palisade Bio lowest stock price was €5.01 and its highest was €5.36 in the past 12 months.
What is Palisade Bio’s market cap?
Palisade Bio’s market cap is €223.67M.
When is Palisade Bio’s upcoming earnings report date?
Palisade Bio’s upcoming earnings report date is Nov 16, 2026 which is in 41 days.
How were Palisade Bio’s earnings last quarter?
Palisade Bio released its earnings results on Aug 10, 2026. The company reported -€0.045 earnings per share for the quarter, beating the consensus estimate of -€0.046 by €0.002.
Is Palisade Bio overvalued?
According to Wall Street analysts Palisade Bio’s price is currently Undervalued.
Does Palisade Bio pay dividends?
Palisade Bio does not currently pay dividends.
What is Palisade Bio’s EPS estimate?
Palisade Bio’s EPS estimate is -0.05.
How many shares outstanding does Palisade Bio have?
Palisade Bio has 174,270,550 shares outstanding.
What happened to Palisade Bio’s price movement after its last earnings report?
Palisade Bio reported an EPS of -€0.045 in its last earnings report, beating expectations of -€0.046. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Palisade Bio?
Currently, no hedge funds are holding shares in DE:7NS0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Palisade Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€9.77 (95.00% Upside)
€9.77 (95.00% Upside)
Blogger Sentiment
Bullish
DE:7NS0 Sentiment 100%
Sector Average 66%
Sector Average 66%
Insider Transactions
Bought Shares
Worth €220.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.75%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
1809.63%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Palisade Bio
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn’s disease. The company has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; license agreement with the Regents of the University of California for sole purpose of maintaining the Newsoara Co-Development; and a co-development and distribution agreement with Newsoara Biopharma Co., Ltd. The company was founded in 2001 and is headquartered in Denver, Colorado.
7NS0 Stock 12 Month Forecast
Average Price Target
€9.77
▲(95.00% Upside)
Technical Analysis
Corbus Pharmaceuticals
―
Eledon Pharmaceuticals
―
―
Orchestra BioMed Holdings
―
Pyxis Oncology
―